Y mAbs Therapeutics (YMAB) — Cash Flow Quality Index

Latest as of December 2022: -7.49x

Y mAbs Therapeutics (YMAB) has a Cash Flow Quality Index of -7.49x as of December 2022. Operating cash flow of $-8.66 Million is below net income of $1.16 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Y mAbs Therapeutics asset portfolio for the complete picture of this company's asset base.

Cash Flow Quality Index

-7.49x
Operating CF / Net Income

Operating Cash Flow

$-8.66 Million
USD

Net Income

$1.16 Million
USD

Data as of

Dec 2022
Most recent filing

Annual Cash Flow Quality Index for Y mAbs Therapeutics (None–None)

Year-by-year earnings quality comparison for Y mAbs Therapeutics. For live market cap and the full company financial profile, see market cap of Y mAbs Therapeutics.

Year Quality Index Operating CF (USD) Net Income YoY Change
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.